21Jul2015 How Are Biotech VCs Performing in the Boom? You’d Be Surprised (Part 2) /Luke Timmerman/1/All, Venture Capital21 Jul 2015 Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.